CHUS

Santiago de Compostela, Spain
Santiago de Compostela, Spain

Time filter

Source Type

SHERBROOKE, QUEBEC--(Marketwired - 16 mai 2017) - Le Groupe DJB et Neptune Technologies & Bioressources (NASDAQ:NEPT)(TSX:NEPT), en collaboration avec l'Université de Sherbrooke, sont fiers d'annoncer la création à Sherbrooke du Consortium Vallée Verte, un partenariat stratégique qui combine les forces et l'expertise respectives des trois partenaires pour créer des produits issus du cannabis à des fins exclusivement médicales et faire de la recherche-développement en la matière; une première dans l'industrie. Sherbrooke Innopole, l'organisme de développement économique de la région, et la Ville de Sherbrooke ont participé activement à la création du Consortium Vallée Verte, conformément à leur mandat de favoriser le dynamisme des environnements économique et universitaire de la région. Les partenaires, avec le soutien de Sherbrooke Innopole et de la Ville de Sherbrooke, entendent mettre en commun leurs expertises de recherche, de culture et d'extraction afin de créer un pôle de recherche-développement en cannabis médical qui sera reconnu non seulement au Canada, mais aussi à l'échelle mondiale. Ils ne ménageront aucun effort pour respecter les réglementations très strictes de cette industrie et pour développer, commercialiser et promouvoir des produits sécuritaires, et ce, avec un constant souci éthique. Ils ont d'ailleurs déjà accompli beaucoup de travail sur les plans botanique, technologique et scientifique, pour favoriser l'efficacité et la qualité de la production, ainsi que pour supporter les études cliniques de l'Université de Sherbrooke. Le maire de Sherbrooke, Bernard Sévigny, fait preuve d'enthousiasme à l'endroit du projet, qui met à profit les atouts de la ville : « Neptune est née dans les laboratoires de l'Université de Sherbrooke, il y a près de vingt ans, et même si l'entreprise fait maintenant des affaires partout dans le monde, elle demeure ancrée à Sherbrooke, tout comme le Groupe DJB, qui est implanté ici depuis sa fondation, en 1982. » « Le regroupement d'institutions de recherche universitaires et d'entreprises établies au sein de la filière des Sciences de la vie est un atout stratégique indéniable, renchérit le maire. Il en résulte un écosystème propice à la collaboration et au développement de synergies. » Josée Fortin, directrice générale de Sherbrooke Innopole, partage cet engouement : « La naissance de ce partenariat est un exemple parfait du mandat de Sherbrooke Innopole, soit de mettre en contact les intervenants du milieu universitaire et les gens d'affaires de la région afin de créer un carrefour scientifique et technologique pour la communauté sherbrookoise. Nous sommes heureux d'appuyer le Consortium Vallée Verte. » « Les objectifs de développement du cannabis médical du Consortium Vallée Verte cadrent avec l'intérêt de plusieurs chercheurs de l'Institut de pharmacologie de Sherbrooke pour la prise en charge de la douleur chronique, indique son directeur, le Pr Éric Marsault. Ceci correspond aux infrastructures acquises récemment avec le soutien de la Fondation canadienne pour l'innovation ainsi que la Stratégie de recherche axée sur le patient dans l'étude de la douleur chronique. La collaboration avec le Consortium nous permettra d'étudier plusieurs questions de recherche importantes sur le rôle des cannabinoïdes dans la douleur pour ultimement offrir aux patients des alternatives efficaces et sécuritaires aux opioïdes, qui, malgré leurs limites, sont actuellement la norme. » « Nos recherches cliniques visent à trouver des solutions menant à un traitement personnalisé et plus adéquat de la douleur, affirme le Pr Serge Marchand, responsable du laboratoire de recherche clinique en neurophysiologie de la douleur du Centre de recherche du CHUS. Le cannabis médical compte parmi les approches thérapeutiques qui méritent notre attention et dont nous devons mieux comprendre les mécanismes pour déterminer chez quels patients elles représentent une solution de rechange aux méthodes conventionnelles. Le Consortium Vallée Verte nous offre une occasion idéale de mobiliser les ressources nécessaires à l'accélération de ces recherches. » « Le Groupe DJB est très fier de se joindre au Consortium Vallée Verte, qui devrait favoriser notre croissance et nous assurer un positionnement avantageux dans un marché effervescent, affirme le président de l'entreprise, Steven Blanchard. Bénéficiant de notre expertise dans le domaine agricole, où nous œuvrons depuis plus de 35 ans, nous avons récemment soumis, en collaboration avec une société affiliée, une demande de licence à Santé Canada pour pouvoir produire du cannabis à des fins médicales. Celle-ci a été faite dans le cadre du Consortium, mais elle vise également à assurer notre présence et notre croissance dans différents secteurs de pointe, notamment la recherche-développement en culture de plantes médicinales. » « Chez Neptune, notre mission est d'offrir à notre clientèle mondiale, grâce à notre expertise scientifique et à nos innovations, les meilleurs produits de nutrition et solutions de bien-être, affirme Jim Hamilton, président et chef de la direction de Neptune Technologies & Bioressources. Ce nouveau segment cadre bien avec notre mission. Étant donné l'excellence de nos employés et les capacités techniques de nos installations sherbrookoises à la fine pointe, et de l'ensemble de l'équipe de Neptune d'ailleurs, nous sentons que nos capacités sur les plans de la qualité, de la conformité, de l'extraction et des applications favoriseront notre réussite et celle du consortium. Nous avons soumis notre demande à Santé Canada récemment - première étape du processus estimé à environ 18 mois - et nous avons hâte de voir comment s'inscrira cette activité potentielle dans notre stratégie de développement et de diversification. » Depuis 1982, Groupe DJB distribue des produits hautement spécialisés à de nombreux clients partout en Amérique. Son service et son dynamisme font du Groupe DJB un partenaire incontournable dans les secteurs agricoles, électriques et environnementaux. Le siège social de Groupe DJB est situé à Sherbrooke, province de Québec. L'Université de Sherbrooke est le cœur d'un des trois pôles de recherche majeurs du Québec. Reconnue pour son sens de l'innovation, l'Université de Sherbrooke est un partenaire de premier plan des gouvernements supérieurs et régionaux pour favoriser le développement social, culturel et économique. Elle se démarque en outre par la forte croissance de ses activités de recherche au cours des dernières années, ses succès en transfert technologique ainsi que ses initiatives en matière d'entrepreneuriat et d'innovation ouverte en collaboration avec les milieux industriels et sociaux. Sherbrooke Innopole est une corporation paramunicipale qui s'appuie sur une équipe pluridisciplinaire d'experts dédiée au développement économique de la Ville de Sherbrooke. Sherbrooke Innopole offre aux entreprises et aux établissements universitaires de la région de Sherbrooke, des services de financement et des services administratifs supérieurs à forte valeur ajoutée. Neptune est une société axée sur les produits de nutrition qui crée des solutions de nutrition uniques et personnalisées et offre des ingrédients spécialisés et des marques de consommation. La Société met au point des solutions clé en main offertes sous diverses formes uniques. Neptune propose aussi de l'huile de krill de première qualité fabriquée dans ses installations de pointe, ainsi que toute une gamme d'autres ingrédients spécialisés, dont des huiles marines et des huiles de graines. Neptune vend son huile de krill de première qualité directement aux consommateurs du Canada et des États-Unis sous la marque OCEANO3MC en ligne au www.oceano3.com. La marque est également vendue sous forme de solution clé en main à divers distributeurs. Le siège social de la Société se trouve à Laval, au Québec. Les énoncés contenus dans le présent communiqué ne portant pas sur des faits courants ou passés constituent des « énoncés prospectifs » au sens de la législation en valeurs mobilières américaine et de la législation en valeurs mobilières canadienne. Ces énoncés prospectifs comportent des risques et incertitudes, connus et inconnus, et sont assujettis à d'autres facteurs inconnus qui pourraient faire en sorte que les résultats réels de Neptune diffèrent de manière importante des résultats passés ou des résultats futurs dont il est question, expressément ou implicitement, dans ces énoncés prospectifs. Outre les énoncés qui décrivent explicitement de tels risques et incertitudes, il y a lieu de préciser que les énoncés qui contiennent des termes tels que « croire », « être d'avis », « prévoir », « avoir l'intention », « s'attendre à », « entendre » ou « planifie » ainsi que l'utilisation du futur dans ces énoncés dénotent la nature incertaine et prospective de ceux-ci. Il est recommandé aux lecteurs de ne pas se fier indûment à ces énoncés prospectifs, qui sont à jour à la date du présent communiqué seulement. L'information prospective contenue dans ce communiqué de presse comprend, mais sans s'y limiter, des informations ou des déclarations concernant notre capacité à développer, produire, fournir, promouvoir ou générer des revenus provenant de la vente de produits à base de cannabis à usage médical ainsi que les résultats de tout essai clinique associé à ceux-ci. Les énoncés prospectifs qui figurent dans le présent communiqué sont présentés sous réserve de la présente mise en garde et la « Mise en garde concernant l'information prospective » figurant à la notice annuelle la plus récente de Neptune (la « notice annuelle »), et le rapport annuel (S.E.C Form 40 F) le plus récent de Neptune disponibles sur SEDAR, à www.SEDAR.com, sur EDGAR, à www.sec.gov/edgar.shtml et dans la section Investisseurs du site Web de Neptune, à www.neptunebiotech.com. Tous les énoncés prospectifs qui figurent dans le présent communiqué de presse sont à jour à la date des présentes. Neptune ne s'engage pas à mettre à jour les énoncés prospectifs suite à de nouveaux renseignements ou à des événements futurs ou pour quelque autre raison que ce soit, sauf dans la mesure exigée par la loi. De plus, les énoncés prospectifs qui figurent dans le présent communiqué comportent généralement d'autres risques et incertitudes qui sont décrits de temps à autre dans les documents publics de Neptune déposés auprès de la Securities and Exchange Commission et des commissions des valeurs mobilières canadiennes. Des renseignements supplémentaires au sujet de ces hypothèses, risques et incertitudes figurent à la rubrique « Facteurs de risque » de la notice annuelle. Ni NASDAQ ni la Bourse de Toronto n'acceptent quelque responsabilité que ce soit quant à la véracité ou à l'exactitude du présent communiqué.


SHERBROOKE, QUEBEC--(Marketwired - May 16, 2017) - Groupe DJB and Neptune Technologies & Bioressources (NASDAQ:NEPT)(TSX:NEPT), in collaboration with the Université de Sherbrooke, are proud to announce the creation of the Sherbrooke-based Green Valley Consortium, a strategic partnership that combines the strengths and expertise of three industry stakeholders to carry out medical cannabis production and research and development activities: an industry first. Sherbrooke Innopole, the region's economic development agency, and the city of Sherbrooke have both been highly active in the establishment of the Green Valley consortium, consistent with their mandate to foster a vibrant economic and academic environment in the region. The Consortium partners, with the assistance of Sherbrooke Innopole and the city of Sherbrooke will work to draw on their combined research, cultural and technical expertise to create a medical cannabis research and development hub that will be recognized both in Canada and abroad. The Consortium intends to develop, commercialize and promote safe, ethically conscious products, while making every effort to abide by stringent industry regulations. Much work has already occurred on the botanical, technological and scientific facets of the endeavour to allow for an effective, high-quality product and to support clinical trials at the Université de Sherbrooke. Mayor Bernard Sévigny expressed his excitement about this project. One built on the strength of his city's assets: "Neptune was born in the labs of the Université de Sherbooke nearly twenty years ago," he said, "and while the company now conducts business internationally, its ties to Sherbrooke remain strong-and so has Groupe DJB, which has operated here since it was founded in 1982." "The irrefutable strategic advantage offered by this alliance of academic research institutions and of well-established businesses in the life sciences sector is fertile ground for the spirit of collaboration and partnership," he added. Josée Fortin, Director General of Sherbrooke Innopole, shares this view: "This partnership perfectly illustrates Sherbrooke Innopole's mission, which is to link the region's academics and business people together to create a scientific and technological center for the local community. We are happy to support the Green Valley Consortium." "The Green Valley Consortium's medical cannabis development objectives are well aligned with work being done on chronic pain management by several researchers at the Pharmacology Institute of Sherbrooke," said the Institute's director, Dr. Éric Marsault. "Like our clinical counterparts, we look forward to pursuing the promising preclinical research avenues that are now within our reach and to one day offer patients alternatives to opioids, which are currently the norm in spite of their limitations." "Our clinical research aims to find personalized, more effective pain treatment solutions," said Dr. Serge Marchand, who supervises the pain research laboratory at the CHUS Research Center. "Medical cannabis is a treatment approach that merits further exploration so that we can better understand its underlying mechanisms and determine which patients should use it as an alternative to conventional treatments. The Green Valley Consortium presents the perfect opportunity to commit the resources necessary to speed up research." "Groupe DJB is very proud to be a part of the Green Valley Consortium," said the company's president, Steven Blanchard. "We expect it to nurture our company's growth and give us a competitive edge in a buoyant marketplace. We have been active in the agricultural sector for over 35 years and recently applied with an affiliated company to Health Canada for a license to produce cannabis for medical purposes. While our application was submitted as part of the Consortium, it should also serve to establish our presence and growth in different leading-edge sectors, including research and development in the field of medicinal plant cultivation." "At Neptune, our mission is to leverage our scientific and innovation expertise to provide our customers globally with the best-available nutritional products and wellness solutions", commented Jim Hamilton, President and CEO of Neptune Technologies & Bioressources. "This new segment fits well with our mission. Given the excellent people and technical capabilities of our "state-of-the-art" site in Sherbrooke, and the entire Neptune team, we feel that our quality, regulatory, extraction, and applications capabilities will position us, and the consortium, for success. We recently submitted our application to Health Canada, the first step in a process expected to take approximately 18 months, and are excited about this business potential within our ongoing corporate development and diversification strategy." Since 1982, Groupe DJB has been distributing highly specialized products to many customers throughout the Americas. Its service and dynamism make the DJB Group an essential partner in the agricultural, electrical and environmental sectors. Groupe DJB's head office is located in Sherbrooke, Quebec. L'Université de Sherbrooke is the heart of one of Québec's three major research centers. Recognized for its sense of innovation, the Université de Sherbrooke is a leading partner of federal, provincial and regional governments in fostering social, cultural and economic development. L'Université de Sherbrooke sets itself apart by the strong growth of its research activities in recent years, its successes in technology transfer as well as in its initiatives in the field of entrepreneurship and open innovation in collaboration with industry and social sectors. Sherbrooke Innopole is a para-municipal corporation dedicated to the economic development of the City of Sherbrooke and relies on a multidisciplinary team of experts. It provides Sherbrooke- based corporations and academic institutions with financing and administrative high-value-added services. Neptune is a nutrition products company focused on the business of customized unique nutrition solutions, specialty ingredients and consumer brands. The company develops turnkey solutions available in various unique delivery forms. Neptune also offers premium krill oil manufactured in its state-of-the art facility and a variety of other specialty ingredients such as marine and seed oils. Neptune sells its premium krill oil under the OCEANO3® brand directly to consumers in Canada and the United States through web sales at www.oceano3.com. OCEANO3 is also sold as a turnkey solution to distributors. The Company's head office is located in Laval, Quebec. Statements in this press release that are not statements of historical or current fact constitute "forward looking statements" within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Forward-looking information in this press release includes, but is not limited to, information or statements about our ability to successfully develop, produce, supply, promote or generate any revenue from the sale of any cannabis-based products for medical use, as well as the results of any clinical trials associated thereto. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement and the "Cautionary Note Regarding Forward-Looking Information" section contained in Neptune's latest Annual Information Form (the "AIF"), which also forms part of Neptune's latest annual report on Form 40-F, and which is available on SEDAR at www.sedar.com, on EDGAR at www.sec.gov/edgar.shtml and on the investor section of Neptune's website at www.neptunebiotech.com. All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under "Risk Factors". Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.


Fernandez-Rodriguez E.,University of Santiago de Compostela | Barreiro J.,University of Santiago de Compostela | Marazuela M.,Autonomous University of Madrid | Pereiro I.,CHUS | And 6 more authors.
Neuroendocrinology | Year: 2011

Objectives: To investigate the prevalence of pituitary stalk dysgenesis (PSD) in adult hypopituitary patients by describing the chronology of hormone deficiencies and their potential correlation with traumatic delivery, mutations in genes required for pituitary development and function and pituitary stalk visibility on MRI. Design: Retrospective and prospective study involving 231 hypopituitary patients, including 26 diagnosed with PSD. Clinical, biochemical and radiological studies were reviewed. Molecular analyses of HESX1, LHX4,PROP1 and POU1F1 genes were performed prospectively. Results: PSD was present in 11.2% of hypopituitary patients. PSD was diagnosed before 14 years of age in 46.2% of cases, between 14 and 18 years of age in 23%, and in adulthood in 30.8%. Perinatal complications or gene mutations were present in 26.9 and 4.3% of patients, respectively. At first assessment, 92.3% of patients had growth hormone (GH) deficiency. 26.9% presented as combined pituitary deficiencies and 7.6% as panhypopituitarism. Hormone deficiencies were progressive during follow-up in 84.6%. 96% progressed to multiple deficiencies and 46% to panhypopituitarism. No significant association was found between hormonal dysfunction and previous perinatal damage or breech delivery (p = 0.17), PROP1 mutations (p = 0.26) or pituitary stalk visibility on MRI (p = 0.52). No mutations in POU1F1, HESX1 and LHX-4 genes were detected. Conclusion: In this study, PSD prevalence in adult hypopituitary patients was 11.2%. Typical clinical presentation includes isolated or combined pituitary hormone deficiencies during the pediatric age, which usually progress to combined or complete hypopituitarism in adulthood. Phenotype is highly variable depending on hormone profile and age at onset. Copyright © 2011 S. Karger AG.


News Article | November 15, 2016
Site: www.eurekalert.org

A study finds that smoking or being overweight makes it more difficult for patients with rheumatoid arthritis to achieve optimal control of inflammation and symptoms, despite standard of care treatment. American and Canadian researchers, who collected data on more than 1,100 patients at multiple sites, presented their findings at the American College of Rheumatology/Association of Rheumatology Health Professionals annual meeting on November 15 in Washington, DC. "Early, aggressive treatment to achieve remission is the primary goal of therapy and can be best achieved early on when treating patients with newly diagnosed rheumatoid arthritis, as early disease control is associated with improved long-term outcomes," said Vivian Bykerk, MD, senior investigator and director of the Inflammatory Arthritis Center of Excellence at Hospital for Special Surgery. "We have previously shown that individuals with excess weight are less likely to achieve sustained remission in the first three years after diagnosis. Here we explore the impact of smoking and being overweight or obese on the ability to achieve good control of symptoms and inflammation in men and women with rheumatoid arthritis." Data were collected at 19 sites across Canada as part of the CATCH (Canadian Early Arthritis Cohort) Study. The multicenter study included rheumatoid arthritis patients diagnosed within 12 months of symptom onset. Researchers looked at the patient's disease activity score, known as the DAS, when they entered the study and at follow-up visits. The DAS is based on the number of swollen and tender joints, a blood test that reflects inflammation, and the patient's own description of their arthritis symptoms over the prior week. After the initial enrollment, patients were seen by their rheumatologist as part of their usual care for follow up every three months in the first year, every six months in the second year, and annually thereafter. Data about their arthritis were collected at each visit. The researchers analyzed how gender, excess weight and smoking (current/former/never) affected symptoms when patients entered the study and over time. The study included 1,109 patients with a mean age of 54 at study onset. Almost all of them were being treated with methotrexate and/or another conventional oral medication when they enrolled. Most of the participants (72%) were female. Among the women, 31% were overweight, 32% were obese, and 15% currently smoked. Among the males, 44% were overweight, 35% were obese and 22% currently smoked. Sex, excess weight and smoking were not significantly associated with symptom severity early on, when patients entered the study. However, all three factors influenced how much symptoms improved over time. The average rate of improvement in the disease activity score was lower in women compared to men. Less symptom improvement was also seen in patients who were overweight or obese compared with those of a healthy weight. Current smokers also saw less symptom relief compared to nonsmokers over time. Former smokers, however, did not do worse than those who had never smoked. The most dramatic differences in symptoms were seen in patients who were overweight or obese and smoked. These patients had considerably worse outcomes over time compared to nonsmoking patients with a healthy weight. "These results contribute to growing evidence of how lifestyle impacts how well patients may respond to treatment and the potential value of referring them to proven community-based smoking cessation and weight management programs," Dr. Bykerk concluded. Authors: Susan J. Bartlett1,2, Orit Schieir3, Kathleen Andersen4, Gilles Boire5, Boulos Haraoui6, Carol Hitchon7, Edward Keystone8, Janet E. Pope9, J Carter Thorne10, Diane Tin11, Vivian P. Bykerk12 and Canadian Early Arthritis Cohort (CATCH) Investigators, 1Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, 2Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3University of Toronto, Toronto, ON, Canada, 4Rheumatology, Hospital for Special Surgery, New York, NY, 5Rheumatology Division, CHUS - Sherbrooke University, Sherbrooke, QC, Canada, 61551, Ontario Street East, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, 7University of Manitoba, Winnipeg, MB, Canada, 8Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, 9University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 10Southlake Regional Health Centre, Newmarket, ON, Canada, 11The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, 12Divison of Rheumatology, Hospital for Special Surgery, New York, NY Hospital for Special Surgery (HSS) is the world's largest academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 2 in rheumatology by U.S. News & World Report (2016-2017), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The hospital's research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at http://www. .


Lamas M.J.,Complejo Hospitalario Universitario of Santiago | Duran G.,Complejo Hospitalario Universitario of Santiago | Balboa E.,Molecular Medicine Unit | Bernardez B.,Complejo Hospitalario Universitario of Santiago | And 7 more authors.
Pharmacogenomics | Year: 2011

Aim: Polymorphisms in the metabolism, detoxification or DNA repair pathways have been proposed as potential predictors of response to 5-fluorouracil and oxaliplatin. We have studied the predictive value of a set of germline genetic polymorphisms in metastatic colorectal cancer patients treated with mFolfox-6. Materials & methods: A total of 72 patients, comprising 50 men (69.4%) and 22 women (30.6%), were included after the signing of an informed consent form. Median age was 65.5 years (range: 32-80). All participants received mFolfox-6. DNA was extracted from peripheral blood samples and genotyped by direct sequencing, SnapShot®Â and multiplex PCR techniques. Eight polymorphisms within six genes were investigated: TS 5́Ấ-UTR (variable number tandem repeat + G/C), TS 3́-UTR (TS1494del6); MTHFR C677T and A1298C; GSTP1 I105V; ERCC1 C118T; XPD Lys751Gln and XRCC1 Arg399Gln. Association was evaluated by univariate analysis, and Cox regression and Kaplan-"Meier assessed survival. The local ethics committee approved the pharmacogenetic study protocol and all subjects signed an informed consent before participating in the study. Results: The sample was in Hardy-"Weinberg equilibrium. Only XPD Lys751Gln was found to be significantly associated with a favorable progression-free survival (PFS). Median PFS for XPD Lys751Gln patients (n = 33) was 16 months (95% CI: 9.2-"22.7), 10 months (95% CI: 6.1-"13.9) for Gln/Gln (n = 11) and 8 months (95% CI: 5.8-"10.2) for Lys/Lys (n = 28), p = 0.019. The increased risk of progression was: 1.93 (95% CI: 1.13-"13.30; p = 0.017) for Lys/Lys and 2.1 (95% CI: 1.01-"4.22; p = 0.047) for Gln/Gln. Patients with one or two Val alleles of GSTP1 tended to a lower risk of progression compared with Ile/Ile homozygotes, p = 0.067. When XPD Lys751Gln and GSTP1 were analyzed jointly, patients who carried one or two favorable genotypes, XPD Lys751Gln and Val, had a longer median PFS: 11 months (95% CI: 7.4-"14.6) compared with six (95% CI: 4.6-7.4) with unfavorable genotypes, p < 0.001. Conclusion: In metastatic colorectal cancer patients treated with mFolfox-6, the combination of haplotype XPD Lys751Gln-GSTP1 105Val seems to predict the risk of progression. © 2011 Future Medicine Ltd.


Poder T.G.,UETMIS and CRCHUS | He J.,University of Sherbrooke | Simard C.,CH of Chicoutimi | Pasquier J.-C.,CHUS
Patient Preference and Adherence | Year: 2014

Objective: To measure the willingness to pay (WTP) of women aged 18–45 years to receive drug treatment for ovulation induction (ie, the social value of normal cycles of ovulation for a woman of childbearing age) in order to feed the debate about the funding of fertility cares.Setting: An anonymous questionnaire was used over the general population of Quebec.Participants: A total of 136 subjects were recruited in three medical clinics, and 191 subjects through an online questionnaire.Method: The questionnaire consisted of three parts: introduction to the problematic, socioeconomic data collection to determine factors influencing the formation of WTP, and a WTP question using the simple bid price dichotomous choice elicitation technique. The econometric estimation method is based on the “random utility theory.” Each subject responding to our questionnaire could express her uncertainty about the answer to our WTP question by choosing the answer “I do not know.”Outcome measure: The WTP in Canadian dollars of women aged 18–45 years to receive drug treatment for ovulation induction.Results: Results are positive and indicate an average WTP exceeding 4,800 CAD, which is much more than the drug treatment cost. There is no evidence of sample frame bias or avidity bias across the two survey modes that cannot be controlled in econometric estimates.Conclusion: Medical treatment for ovulation induction is highly socially desirable in Quebec. © 2014 Poder et al.


PubMed | CH of Chicoutimi, UETMIS and CRCHUS, Université de Sherbrooke and CHUS
Type: | Journal: Patient preference and adherence | Year: 2014

To measure the willingness to pay (WTP) of women aged 18-45 years to receive drug treatment for ovulation induction (ie, the social value of normal cycles of ovulation for a woman of childbearing age) in order to feed the debate about the funding of fertility cares.An anonymous questionnaire was used over the general population of Quebec.A total of 136 subjects were recruited in three medical clinics, and 191 subjects through an online questionnaire.THE QUESTIONNAIRE CONSISTED OF THREE PARTS: introduction to the problematic, socioeconomic data collection to determine factors influencing the formation of WTP, and a WTP question using the simple bid price dichotomous choice elicitation technique. The econometric estimation method is based on the random utility theory. Each subject responding to our questionnaire could express her uncertainty about the answer to our WTP question by choosing the answer I do not know.The WTP in Canadian dollars of women aged 18-45 years to receive drug treatment for ovulation induction.Results are positive and indicate an average WTP exceeding 4,800 CAD, which is much more than the drug treatment cost. There is no evidence of sample frame bias or avidity bias across the two survey modes that cannot be controlled in econometric estimates.Medical treatment for ovulation induction is highly socially desirable in Quebec.


Anton Aparicio L.M.,UDC | Anton Aparicio L.M.,Oncology Group | Medina Villaamil V.,Oncology Group | Aparicio Gallego G.,Oncology Group | And 9 more authors.
Cancer Genomics and Proteomics | Year: 2011

Background: Mutations in signalling pathways essential for embryonic development often lead to tumourigenesis, as is also true for Notch. The aim of this study was to assess the relationship between Notch1 to -4 and their ligands with anatomopathological features of the patients with renal cell carcinoma (RCC). Materials and Methods: This study investigated the pattern of protein expression in RCC specimens using tissue microarray technology. A total of 80 paraffin-embedded RCC samples were retrospectively analysed together with ACHN and A.704 cell lines. Results: Notch1 showed significant positive correlation with chromophobe RCC, no broken capsule, Furhman grade I and when the number of nodes involved was small [(N=1); p=0.039, 0.016, 0.037 and 0.001, respectively)]. Notch3 showed higher expression when the tumour was located in the right kidney (p=0.048). Conclusion: Notch1 may be useful in the future as a biomarker for the differential diagnosis of different RCC histological subtypes. Notch1 to -3 may also have potential use as a strong prognostic factor.


PubMed | Neurology Service, CHUS and CHU Ste Justine
Type: Journal Article | Journal: European journal of human genetics : EJHG | Year: 2015

CACNA1A loss-of-function mutations classically present as episodic ataxia type 2 (EA2), with brief episodes of ataxia and nystagmus, or with progressive spinocerebellar ataxia (SCA6). A minority of patients carrying CACNA1A mutations develops epilepsy. Non-motor symptoms associated with these mutations are often overlooked. In this study, we report 16 affected individuals from four unrelated families presenting with a spectrum of cognitive impairment including intellectual deficiency, executive dysfunction, ADHD and/or autism, as well as childhood-onset epileptic encephalopathy with refractory absence epilepsy, febrile seizures, downbeat nystagmus and episodic ataxia. Sequencing revealed one CACNA1A gene deletion, two deleterious CACNA1A point mutations including one known stop-gain and one new frameshift variant and a new splice-site variant. This report illustrates the phenotypic heterogeneity of CACNA1A loss-of-function mutations and stresses the cognitive and epileptic manifestations caused by the loss of CaV2.1 channels function, presumably affecting cerebellar, cortical and limbic networks.


Aim: The purpose of this study was to calculate the cost savings associated with using the kaizen approach in our hospital. Methods: Originally developed in Japan, the kaizen approach, based on the idea of continuous improvement, has considerable support in North America, including in the Quebec health care system. This study assessed the first fifteen kaizen projects at the CHUS. Results: Based on an economic evaluation, we showed that using the kaizen approach can result in substantial cost savings. Conclusion: The success of the kaizen approach requires compliance with specific prerequisites. The future of the approach will depend on our ability to comply with these prerequisites. More specifically, such compliance will determine whether the approach is merely a passing fad or a strategy for improving our management style to promote greater efficiency. © S.F.S.P.. Tous droits réservés pour tous pays.

Loading CHUS collaborators
Loading CHUS collaborators